319. SWORD 1 and 2: Switch from TDF Containing Regimen to DTG+RPV Maintains Bone Mineral Density and Decreases Bone Turnover Markers Over 148 Weeks

BACKGROUND: HIV infection and antiretroviral therapy (ART), particularly tenofovir (TDF), is associated with loss of bone mineral density (BMD). The SWORD studies demonstrated noninferiority of the 2-drug regimen (2DR) dolutegravir (DTG) + rilpivirine (RPV) to continuing current triple-therapy ART (...

Descripción completa

Detalles Bibliográficos
Autores principales: Kahl, Lesley, McComsey, Grace A, Coronado Poggio, Monica, Lupo, Sergio, de Wet, Joss, Parks, David A, Wynne, Brian, Gartland, Martin, Angelis, Kostas, Aylott, Alicia, Cupo, Michael, Vandermeulen, Kati, van Wyk, Jean A, Smith, Kimberly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809771/
http://dx.doi.org/10.1093/ofid/ofz360.392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809771/
http://dx.doi.org/10.1093/ofid/ofz360.392

Ejemplares similares